Acadian Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Acadian Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Sell	5,033 -7,774	-61%	-$119K	﹤0.01%	1743
2026 Q1	$177K	Sell	12,807 -55,854	-81%	-$890K	﹤0.01%	1620
2025 Q4	$1.11M	Buy	68,661 +43,320	+171%	+$707K	﹤0.01%	1093
2025 Q3	$378K	Sell	25,341 -45,716	-64%	-$557K	﹤0.01%	1279
2025 Q2	$826K	Sell	71,057 -112,056	-61%	-$1.02M	﹤0.01%	1017
2025 Q1	$1.36M	Buy	183,113 +56,058	+44%	+$431K	﹤0.01%	853
2024 Q4	$760K	Sell	127,055 -50,634	-28%	-$279K	﹤0.01%	981
2024 Q3	$908K	Buy	+177,689	New	+$774K	﹤0.01%	936
2024 Q2	–	Sell	-162,137	Closed	-$519K	–	1731
2024 Q1	$519K	Buy	+162,137	New	+$627K	﹤0.01%	995
2020 Q2	–	Sell	-3,145	Closed	-$87K	–	2211
2020 Q1	$87K	Sell	3,145 -305	-9%	-$8.51K	﹤0.01%	1377
2019 Q4	$103K	Buy	+3,450	New	+$99.1K	﹤0.01%	1446

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Acadian Asset Management's ADPT Position: Q2 2026 in Review

Acadian Asset Management reduced its Adaptive Biotechnologies (ADPT) stake by 61% in Q2 2026, selling an estimated $119K and leaving 5,033 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Acadian Asset Management first reported a position in ADPT in Q4 2019 and has held it in 11 quarters since. The position peaked at $1.36M in Q1 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Acadian Asset Management held 5,033 shares of Adaptive Biotechnologies worth $107K as of Q2 2026.
Acadian Asset Management sold 7,774 Adaptive Biotechnologies shares in Q2 2026, an estimated $119K.
Adaptive Biotechnologies made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1743 holding.
Acadian Asset Management first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 11 quarters since.
Acadian Asset Management's Adaptive Biotechnologies position peaked at $1.36M in Q1 2025.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.